Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18622406 | 0.81 | NMT1 (0.42) | CHRM4NMT1 | |
| SCHEMBL13106183 | 0.81 | HSD11B1 (0.37) | CHRM4PDE10ANMT1PDE2A | |
| SCHEMBL30480710 | 0.72 | ADORA2A (0.45) | KDM4EHTTPDE10APDK1PDK2 | |
| SCHEMBL613838 | 0.72 | ADORA2A (0.45) | KDM4EHTTPDE10APDK1PDK2 | |
| SCHEMBL13106294 | 0.71 | PDE10A (0.40) | CHRM4KDM4EHTTPDE10ANMT1 | |
| SCHEMBL13106176 | 0.71 | KIT (0.44) | CHRM4KDM4EHTTPDE10A | |
| SCHEMBL13106185 | 0.69 | CHRM4 (0.39) | CHRM4HTTPDK1PDK2NMT1 | |
| SCHEMBL21171659 | 0.68 | ADCY10 (0.36) | CHRM4HTTNMT1 | |
| SCHEMBL16369657 | 0.68 | CHRM4 (0.36) | CHRM4NMT1 | |
| SCHEMBL13106281 | 0.68 | CHRM4 (0.38) | CHRM4HTTNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812045-B2 | Antifungal triazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2010-10-12 | — | — | US | disclosed |
| US-20080194661-A1 | Antifungal Triazole Derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194661-A1 | Antifungal Triazole Derivatives | ERG28, CYP51A1, CYP3A43 | CHRM4 4819/4885KDM4E 4335/4885HTT 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.